2025 third_quarter Filing
Q3Lobbying Activities
FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Reconciliation, FY2026, Health related provisions Possible Health policy package Monitor the following: Prescription drug costs, generally VALID Act, Diagnostic Lab Testing Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Monitor the following: Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Law 119-21, One Big Beautiful Bill Act, generally
FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Reconciliation, FY2026, Health related provisions Possible Health policy package Monitor the following: Prescription drug costs, generally VALID Act, Diagnostic Lab Testing Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives